Diseases such as Alzheimer’s disease, epilepsy, type II diabetes, systemic lupus erythematosus, and atherosclerosis are all associated with local accumulation of pro-inflammatory neutrophils [8], and thus might be potential applications for Ripk3-targeted treatments. Here, RIPK3 is linked to systemic lupus erythematosus.